News dal mondo
27
Mar
EDQM shares guidance on reliance-based and fast-track CEP filings
The European Directorate for the Quality of Medicines and HealthCare (EDQM) has published guidelines on how Certification of Suitability (CEP) holders or prospective applicants can request reliance-based or fast-track assessments.
Both pathways offer accelerated assessments of new applications for chemical purity while maintaining the regulatory diligence and rigor of standard CEP reviews. The circumstances in which the pathways can be used are different, with EDQM opening the reliance-based route to companies with certain regulatory approvals and creating the fast-track mechanism to address medicine shortages.
The reliance pathway is open to applicants with Active Substance Master Files (ASMFs) or Drug Master Files (DMFs) that have been assessed and accepted in the EU, European Economic Area, Switzerland, UK, Australia, or Canada since October 2012. The manufacturing process must be the same for the existing and requested approvals. EDQM expects the CEP dossier to be identical to the ASMF or DMF dossier, although it may accept minor updates to the original file.
Applicants may be eligible for a fast-track review when EMA or a national regulator has asked EDQM to help address an active substance or excipient shortage. EDQM will also consider fast-tracking the review of active substances that EMA lists as being subject to an ongoing shortage. The directorate will refuse requests for fast-track assessment based solely on commercial grounds.
On a case-by-case basis, EDQM will consider fast-tracking requests from prospective CEP holders that can clearly show an accelerated review would deliver significant benefit to patients or align with the objectives of the EU Critical Medicines Act. EDQM will consider the criticality, therapeutic indication, and availability of the active substance when assessing the impact of a fast-track review on patients.
EDQM has established the same timelines for reliance-based and fast-track reviews. The directorate will complete the initial evaluation within 46 working days, after which the applicant will have 30 calendar days to respond. EDQM has 23 working days to complete its subsequent evaluation. Initial assessments take up to 115 working days under the standard procedure. [EDQM]
13
Mag
Deal on tackling EU shortages of essential medicines
Prioritise investment in EU manufacturing capacity to increase autonomy “Buy European”...
12
Mag
Chimica: Bruxelles non rivedra' le norme REACH
Bruxelles non rivedra' le norme Reach, troppa incertezza per il settore La Commissione europea ha...
08
Mag
Farmaceutica, Gemmato: 'per Testo unico deadline entro dicembre'
"Il Testo unico sulla legislazione farmaceutica, che ha come obiettivo quello compendiare 800 fra...
08
Mag
Min. Salute Gemmato: “Testo unico farmaceutico entro dicembre 2026”
Il sottosegretario alla Salute indica la tabella di marcia della riforma. Al centro accesso ai farmaci...
le ultime news
27 Feb
US FDA Announces the 2026 QMM Prototype Assessment Protocol Evaluation Program
27 Feb
Quantum computing nelle life sciences: a Milano un convegno per l’industria farmaceutica
24 Feb
Industry clamors for clearer guidance on transition to ICH M4Q(R2)
23 Feb
USA . La Corte Suprema boccia i dazi globali di Trump: cosa cambia e perché il pharma resta nel mirino
20 Feb
NerPharma acquistata da un colosso farmaceutico francese
20 Feb
Generic industry against giving fee breaks to firms setting up operations in the US
20 Feb
US FDA: svolta storica: basterà un solo studio registrativo per approvare i nuovi farmaci